Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM2 | Q9P1W9 | 10/20 | 0.68 |
| ▸ | PIM1 | P11309 | 9/20 | 0.68 |
| ▸ | PIM3 | Q86V86 | 9/20 | 0.68 |
| ▸ | BTK | Q06187 | 4/20 | 0.44 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.43 |
| ▸ | F10 | P00742 | 1/20 | 0.41 |
| ▸ | AURKA | O14965 | 3/20 | 0.40 |
| ▸ | PDPK1 | O15530 | 3/20 | 0.40 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2420001 | 1.00 | PIM2 (0.68) | PIM2PIM1PIM3BTKMAP4K4 | |
| SCHEMBL2426637 | 0.93 | PIM2 (0.69) | PIM2PIM1PIM3BTKMAP4K4 | |
| SCHEMBL2426642 | 0.93 | PIM2 (0.69) | PIM2PIM1PIM3BTKMAP4K4 | |
| SCHEMBL2426644 | 0.93 | PIM2 (0.69) | PIM2PIM1PIM3BTKMAP4K4 | |
| SCHEMBL2426638 | 0.93 | PIM2 (0.69) | PIM2PIM1PIM3BTKMAP4K4 | |
| SCHEMBL16468720 | 0.88 | PIM1 (0.77) | PIM2PIM1PIM3BTK | |
| SCHEMBL12282933 | 0.88 | PIM1 (0.77) | PIM2PIM1PIM3BTK | |
| SCHEMBL16468722 | 0.88 | PIM1 (0.77) | PIM2PIM1PIM3BTK | |
| SCHEMBL2425479 | 0.87 | PIM2 (0.90) | PIM2PIM1PIM3BTKMAP4K4 | |
| SCHEMBL13538032 | 0.86 | PIM1 (0.74) | PIM2PIM1PIM3BTKMAP4K4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150051185-A1 | Chemical Compounds 251 | ASTRAZENECA AB (SE) | 2015-02-19 | — | — | US | disclosed |
| US-20150051185-A1 | Chemical Compounds 251 | ASTRAZENECA AB (SE) | 2015-02-19 | — | — | US | disclosed |
| US-8901307-B2 | Chemical compounds 251 | ASTRAZENECA AB (SE) | 2014-12-02 | — | — | US | disclosed |
| US-8901307-B2 | Chemical compounds 251 | ASTRAZENECA AB (SE) | 2014-12-02 | — | — | US | disclosed |
| US-20110218182-A1 | CHEMICAL COMPOUNDS 251 | ASTRAZENECA AB (SE) | 2011-09-08 | — | — | US | disclosed |
| US-20110218182-A1 | CHEMICAL COMPOUNDS 251 | ASTRAZENECA AB (SE) | 2011-09-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110218182-A1 | CHEMICAL COMPOUNDS 251 | PIM1, PIM3, PIM2 | PIM2 3/4885PIM1 1/4885PIM3 2/4885 |
| US-20150051185-A1 | Chemical Compounds 251 | PIM1, PIM3, PIM2 | PIM2 3/4885PIM1 1/4885PIM3 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.